Good News: Polio Vaccine Maker BIBCOL will Manufacture 2 Crore Doses of Covaxin Every Month at its Bulandshahar Plant in Uttar Pradesh

New Delhi: The wholly indigenous Covid-19 vaccine Covaxin, produced in collaboration with the Indian Council of Medical Research (ICMR) of the Government of India and the vaccine company Bharat Biotech, will be produced in Bulandshahr, the nearest city of Delhi. For this, the central government has given the green signal. In the Chola area of ​​Bulandshahar, a company named Bibakol will produce Covaxin and will produce around 2 crore vaccine doses every month. For this, an MoU has also been signed between Bibcole and Bharat Biotech and a budget of Rs 30 crore has also been approved by the Union Ministry of Health.

Bibcole ie Bharat Immunological and Biological Limited (BIBCOL) is a Government of India company and to date, it produces polio vaccine in the country. But at present, the corona vaccine is considered to be the most in need in the country, so BIBCOL has been asked to produce the corona vaccine. BIBCOL produces about 60 percent of the polio vaccine produced in the country. This means that the company has a large capacity for vaccine production.

Meanwhile, there is also news that an expert committee on Tuesday recommended testing for the second/third stage of India Biotech’s Covid-19 vaccine covaxine for children (aged 2-18). Official sources gave this information. He told that this test will be done at various places including AIIMS in Delhi and Patna and Meditrina Institute of Medical Sciences, Nagpur.

The Covid-19 Subject Expert Committee of the Central Drugs Standard Control Organization (CDSCO) on Tuesday discussed the application made by Bharat Biotech to increase the safety and immunity of its covaxine vaccine in two-to-18-year-old children. It was requested to allow the second/third phase of the test to assess other things including. A source said that after detailed deliberations on the company’s application, the committee recommended allowing the proposed second/third stage test.